N
128.39
0.35 (0.27%)
| 前收盘价格 | 128.04 |
| 收盘价格 | 127.88 |
| 成交量 | 810,218 |
| 平均成交量 (3个月) | 1,053,864 |
| 市值 | 12,733,913,088 |
| 市盈率 (P/E TTM) | 37.99 |
| 预期市盈率 (P/E Forward) | 25.77 |
| 价格/销量 (P/S) | 5.44 |
| 股市价格/股市净资产 (P/B) | 4.89 |
| 52周波幅 | |
| 利润日期 | 30 Oct 2025 |
| 营业毛利率 | 12.68% |
| 营业利益率 (TTM) | 4.14% |
| 稀释每股收益 (EPS TTM) | 2.95 |
| 季度收入增长率 (YOY) | 11.10% |
| 季度盈利增长率 (YOY) | -81.80% |
| 总债务/股东权益 (D/E MRQ) | 19.45% |
| 流动比率 (MRQ) | 3.13 |
| 营业现金流 (OCF TTM) | 529.90 M |
| 杠杆自由现金流 (LFCF TTM) | 235.48 M |
| 资产报酬率 (ROA TTM) | 8.75% |
| 股东权益报酬率 (ROE TTM) | 12.43% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看涨 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看涨 | 混合的 | |
| 股票 | Neurocrine Biosciences, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
0.6
| 分析师共识 | 4.0 |
| 内部交易活动 | -4.0 |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.60 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Mid Core |
| 内部持股比例 | 1.06% |
| 机构持股比例 | 98.86% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 182.00 (Goldman Sachs, 41.76%) | 购买 |
| 中 | 168.50 (31.24%) | |
| 低 | 141.00 (Wedbush, 9.82%) | 购买 |
| 平均值 | 163.10 (27.04%) | |
| 总计 | 9 购买, 1 保留 | |
| 平均价格@调整类型 | 129.86 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 01 Aug 2025 | 175.00 (36.30%) | 购买 | 128.91 |
| JP Morgan | 31 Jul 2025 | 145.00 (12.94%) | 保留 | 128.23 |
| Morgan Stanley | 31 Jul 2025 | 158.00 (23.06%) | 购买 | 128.23 |
| 22 Jul 2025 | 150.00 (16.83%) | 购买 | 132.75 | |
| Piper Sandler | 31 Jul 2025 | 175.00 (36.30%) | 购买 | 128.23 |
| RBC Capital | 31 Jul 2025 | 144.00 (12.16%) | 购买 | 128.23 |
| 02 Jun 2025 | 145.00 (12.94%) | 购买 | 124.56 | |
| Stifel | 31 Jul 2025 | 174.00 (35.52%) | 购买 | 128.23 |
| Wedbush | 31 Jul 2025 | 141.00 (9.82%) | 购买 | 128.23 |
| Truist Securities | 21 Jul 2025 | 163.00 (26.96%) | 购买 | 131.83 |
| Goldman Sachs | 10 Jul 2025 | 182.00 (41.76%) | 购买 | 134.92 |
| UBS | 09 Jul 2025 | 174.00 (35.52%) | 购买 | 133.51 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| GORMAN KEVIN CHARLES | - | 125.60 | -106,322 | -13,354,043 |
| 累积净数量 | -106,322 | |||
| 累积净值 ($) | -13,354,043 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 125.60 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | 董事 | 07 Aug 2025 | 自动卖出 (-) | 106,322 | 125.60 | 13,354,043 |
| GORMAN KEVIN CHARLES | 董事 | 07 Aug 2025 | 执行期权 | 106,322 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合